Trial Profile
Apatinib mesylate tablets combined with docetaxel for the taxane based chemotherapy in the treatment of the failure of HER-2 negative metastatic breast cancer prospective, open, single arm clinical study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2016
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Rivoceranib (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 27 Oct 2016 New trial record